Literature DB >> 25624352

The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.

B Vijayalakshmi Ayyar1, K Roger Aoki2, M Zouhair Atassi3.   

Abstract

Botulinum neurotoxins (BoNTs) possess unique specificity for nerve terminals. They bind to the presynaptic membrane and then translocate intracellularly, where the light-chain endopeptidase cleaves the SNARE complex proteins, subverting the synaptic exocytosis responsible for acetylcholine release to the synaptic cleft. This inhibits acetylcholine binding to its receptor, causing paralysis. Binding, an obligate event for cell intoxication, is believed to occur through the heavy-chain C-terminal (HC) domain. It is followed by toxin translocation and entry into the cell cytoplasm, which is thought to be mediated by the heavy-chain N-terminal (HN) domain. Submolecular mapping analysis by using synthetic peptides spanning BoNT serotype A (BoNT/A) and mouse brain synaptosomes (SNPs) and protective antibodies against toxin from mice and cervical dystonia patients undergoing BoNT/A treatment revealed that not only regions of the HC domain but also regions of the HN domain are involved in the toxin binding process. Based on these findings, we expressed a peptide corresponding to the BoNT/A region comprising HN domain residues 729 to 845 (HN729-845). HN729-845 bound directly to mouse brain SNPs and substantially inhibited BoNT/A binding to SNPs. The binding involved gangliosides GT1b and GD1a and a few membrane lipids. The peptide bound to human or mouse neuroblastoma cells within 1 min. Peptide HN729-845 protected mice completely against a lethal BoNT/A dose (1.05 times the 100% lethal dose). This protective activity was obtained at a dose comparable to that of the peptide from positions 967 to 1296 in the HC domain. These findings strongly indicate that HN729-845 and, by extension, the HN domain are fully programmed and equipped to bind to neuronal cells and in the free state can even inhibit the binding of the toxin.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25624352      PMCID: PMC4363415          DOI: 10.1128/IAI.00063-15

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

Review 1.  Botulinum neurotoxin: a marvel of protein design.

Authors:  Mauricio Montal
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

2.  Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation.

Authors:  Desigan Kumaran; Subramaniam Eswaramoorthy; William Furey; Jorge Navaza; Martin Sax; Subramanyam Swaminathan
Journal:  J Mol Biol       Date:  2008-12-24       Impact factor: 5.469

3.  Crystal structure of botulinum neurotoxin type A and implications for toxicity.

Authors:  D B Lacy; W Tepp; A C Cohen; B R DasGupta; R C Stevens
Journal:  Nat Struct Biol       Date:  1998-10

4.  Phospholipase D activity facilitates Ca2+-induced aggregation and fusion of complex liposomes.

Authors:  R A Blackwood; J E Smolen; A Transue; R J Hessler; D M Harsh; R C Brower; S French
Journal:  Am J Physiol       Date:  1997-04

Review 5.  Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.

Authors:  M Z Atassi; M Oshima
Journal:  Crit Rev Immunol       Date:  1999       Impact factor: 2.214

6.  Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A.

Authors:  J A Chaddock; J R Purkiss; L M Friis; J D Broadbridge; M J Duggan; S J Fooks; C C Shone; C P Quinn; K A Foster
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

7.  Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics.

Authors:  Jiafu Wang; Jianghui Meng; Gary W Lawrence; Tomas H Zurawski; Astrid Sasse; MacDara O Bodeker; Marcella A Gilmore; Ester Fernández-Salas; Joseph Francis; Lance E Steward; K Roger Aoki; J Oliver Dolly
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

8.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.

Authors:  Jason R Barash; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

9.  Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain.

Authors:  John A Chaddock; John R Purkiss; Frances C G Alexander; Sarah Doward; Sarah J Fooks; Lorna M Friis; Yper H J Hall; Elizabeth R Kirby; Nicola Leeds; Hilary J Moulsdale; Anthony Dickenson; G Mark Green; Wahida Rahman; Rie Suzuki; Michael J Duggan; Conrad P Quinn; Clifford C Shone; Keith A Foster
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

10.  CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid.

Authors:  R Weigert; M G Silletta; S Spanò; G Turacchio; C Cericola; A Colanzi; S Senatore; R Mancini; E V Polishchuk; M Salmona; F Facchiano; K N Burger; A Mironov; A Luini; D Corda
Journal:  Nature       Date:  1999-11-25       Impact factor: 49.962

View more
  7 in total

1.  Enhancing toxin-based vaccines against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Madison Zuverink; Eric A Johnson; Sabine Pellet; Joseph T Barbieri
Journal:  Vaccine       Date:  2018-01-04       Impact factor: 3.641

2.  Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.

Authors:  Jaeyoon Byun; Seongsung Kwak; Jin-Hee Kwon; Minhee Shin; Dong-Kyu Lee; Chang-Hoon Rhee; Won-Ho Kang; Jae-Wook Oh; Deu John M Cruz
Journal:  Toxins (Basel)       Date:  2022-05-25       Impact factor: 5.075

Review 3.  Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception.

Authors:  Dong-Wan Kim; Sun-Kyung Lee; Joohong Ahnn
Journal:  Toxins (Basel)       Date:  2015-06-30       Impact factor: 4.546

4.  Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E.

Authors:  Zhen Li; Jiansheng Lu; Xiao Tan; Rong Wang; Qing Xu; Yunzhou Yu; Zhixin Yang
Journal:  Toxins (Basel)       Date:  2022-02-11       Impact factor: 4.546

5.  Neurotrophic effects of Botulinum neurotoxin type A in hippocampal neurons involve activation of Rac1 by the non-catalytic heavy chain (HCC/A).

Authors:  Luis Solabre Valois; Vanilla Hua Shi; Paul Bishop; Bangfu Zhu; Yasuko Nakamura; Kevin A Wilkinson; Jeremy M Henley
Journal:  IBRO Neurosci Rep       Date:  2021-05-13

6.  Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin.

Authors:  B Vijayalakshmi Ayyar; Rajeev B Tajhya; Christine Beeton; M Zouhair Atassi
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379

7.  Endocytosis, trafficking and exocytosis of intact full-length botulinum neurotoxin type a in cultured rat neurons.

Authors:  Luis Solabre Valois; Kevin A Wilkinson; Yasuko Nakamura; Jeremy M Henley
Journal:  Neurotoxicology       Date:  2020-02-20       Impact factor: 4.294

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.